View Item 

Show simple item record

Combining information to estimate adherence in studies of pre- exposure prophylaxis for HIV prevention: Application to HPTN 067
dc.contributor.authorHughes, James P.
dc.contributor.authorWilliamson, Brian D.
dc.contributor.authorKrakauer, Chloe
dc.contributor.authorChau, Gordon
dc.contributor.authorOrtiz, Brayan
dc.contributor.authorWakefield, Jon
dc.contributor.authorHendrix, Craig
dc.contributor.authorAmico, K. Rivet
dc.contributor.authorHoltz, Timothy H.
dc.contributor.authorBekker, Linda-Gail
dc.contributor.authorGrant, Robert
dc.date.accessioned2022-03-07T03:11:41Z
dc.date.available2023-04-06 22:11:39en
dc.date.available2022-03-07T03:11:41Z
dc.date.issued2022-03-15
dc.identifier.citationHughes, James P.; Williamson, Brian D.; Krakauer, Chloe; Chau, Gordon; Ortiz, Brayan; Wakefield, Jon; Hendrix, Craig; Amico, K. Rivet; Holtz, Timothy H.; Bekker, Linda-Gail ; Grant, Robert (2022). "Combining information to estimate adherence in studies of pre- exposure prophylaxis for HIV prevention: Application to HPTN 067." Statistics in Medicine 41(6): 1120-1136.
dc.identifier.issn0277-6715
dc.identifier.issn1097-0258
dc.identifier.urihttps://hdl.handle.net/2027.42/171835
dc.publisherJohn Wiley
dc.subject.otheradherence
dc.subject.otherHIV
dc.subject.otherlatent variable
dc.subject.otherpharmacokinetic model
dc.subject.otherpre- exposure prophylaxis
dc.titleCombining information to estimate adherence in studies of pre- exposure prophylaxis for HIV prevention: Application to HPTN 067
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelPublic Health
dc.subject.hlbsecondlevelStatistics and Numeric Data
dc.subject.hlbsecondlevelMedicine (General)
dc.subject.hlbtoplevelHealth Sciences
dc.subject.hlbtoplevelSocial Sciences
dc.subject.hlbtoplevelScience
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/171835/1/sim9321.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/171835/2/sim9321-sup-0001-supinfo.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/171835/3/sim9321_am.pdf
dc.identifier.doi10.1002/sim.9321
dc.identifier.sourceStatistics in Medicine
dc.identifier.citedreferenceGrant RM, Lama JR, Anderson PL, et al. Pre- exposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010; 363: 2587 - 2599.
dc.identifier.citedreferenceMarrazzo JM, Ramjee G, Richardson BA, et al. Tenofovir- based pre- exposure prophylaxis for HIV infection among African women. N Engl J Med. 2015; 372: 509 - 518.
dc.identifier.citedreferenceJiang X, Ye L, Zhou B, et al. Pre- exposure prophylaxis for the prevention of HIV infection in high risk populations: a meta- analysis of randomized controlled trials. PLoS One. 2014; 9: e87674.
dc.identifier.citedreferenceHendrix CW, Andrade A, Bumpus NN, et al. Dose frequency ranging pharmacokinetic study of tenofovir- emtricitabine after directly observed dosing in healthy volunteers to establish adherence benchmarks (HPTN 066). AIDS Res Hum Retrovir. 2016; 35: 32 - 43.
dc.identifier.citedreferenceHaberer JE. Current concepts for PrEP adherence: in the PrEP revolution; from clinical trials to routine practice. Curr Opin HIV AIDS. 2016; 11: 10 - 17.
dc.identifier.citedreferenceWilliams AB, Amico KR, Bova C, Womak JA. A proposal for quality standards for measuring medication adherence in research. AIDS Behav. 2013; 17: 284 - 297.
dc.identifier.citedreferenceHendrix CW, Chen BA, Guddera V, et al. MTN- 001: randomized pharmacokinetic cross- over study comparing tenofovir vaginal gel and oral tablets in vaginal tissue and other compartments. PLoS One. 2013; 8: e55013.
dc.identifier.citedreferenceBurns RN, Hendrix CW, Chaturvedula A. Population pharmacokinetics of tenofovir and tenofovir- diphosphate in healthy women. J Clin Pharmacol. 2015; 55: 629 - 638.
dc.identifier.citedreferenceChaturvedula A, Fossler MJ, Hendrix CW. Estimation of tenofovir’s population pharmacokinetic parameters without reliable dosing histories and application to tracing dosing history using simulation strategies. Clin Pharm. 2014; 54: 150 - 160.
dc.identifier.citedreferenceEvans M, Guttman I, Haitovsky Y, Swartz TB. Bayesian analysis of binary data subject to misclassification. In: Berry DA, Chaloner KM, Geweke JK, eds. Bayesian Analysis in Statistics and Econometrics. Hoboken, NJ: John Wiley; 1996: 67 - 77.
dc.identifier.citedreferenceGibiansky L, Ekaterina G, Valérie C, Nicolas F, Franziska SS. Methods to detect non- compliance and minimize its impact on population PK parameter estimates. Paper presented at: Population Approach Group in Europe (PAGE); 2013.
dc.identifier.citedreferenceAnderson PL, Liu AY, Castillo- Mancilla JR, et al. Intracellular tenofovir- diphosphate and emtricitabine- triphosphate in dried blood spots following directly observed therapy. Antimicrob Agents Chemother. 2017; 62: e01710 - e01717.
dc.identifier.citedreferenceBerg KM, Arnsten JH. Practical and conceptual challenges in measuring antiretroviral adherence. J Acquir Immune Defic Syndr. 1999; 43 ( Supp 1 ): S79 - S87.
dc.identifier.citedreferenceSimoni JM, Kurth AE, Pearson CR, Pantalone DW, Merrill JO, Frick PA. Self- report measures of antiretroviral therapy adherence: a review with recommendations for HIV research and clinical management. AIDS Behav. 2006; 10: 227 - 245.
dc.identifier.citedreferenceMolina JM, Capitant C, Spire B, et al. On- demand pre- exposure prophylaxis in men at high risk for HIV- 1 infection. N Engl J Med. 2015; 373: 2237 - 2246.
dc.identifier.citedreferenceBaeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012; 367: 399 - 410.
dc.identifier.citedreferenceThigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral pre- exposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012; 367: 423 - 434.
dc.identifier.citedreferenceChoopanya K, Martin M, Suntharasamai P, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double- blind, placebo- controlled phase 3 trial. Lancet. 2013; 381: 2083 - 2090.
dc.identifier.citedreferenceVan Damme L, Corneli A, Ahmed K, et al. Pre- exposure prophylaxis for HIV infection among African women. N Engl J Med. 2012; 367: 411 - 422.
dc.identifier.citedreferenceCottrell ML, Yang KH, Prince HM, et al. A translational pharmacology approach to predicting outcomes of pre- exposure prophylaxis against HIV in men and women using tenofovir disoproxil fumarate with or without emtricitabine. J Infect Dis. 2016; 214: 55 - 64.
dc.identifier.citedreferenceMadrasi K, Chaturvedula A, Haberer JE, et al. Markov mixed effects modeling using electronic adherence monitoring records identifies influential covariates to HIV pre- exposure prophylaxis. J Clin Pharmacol. 2017; 57: 606 - 615.
dc.identifier.citedreferenceBekker LG, Roux S, Sebastian E, et al. A randomized open label trial of daily and non- daily pre exposure prophylaxis in African women: the HPTN 067/ADAPT cape town trial. Lancet HIV. 2018; 5: e68 - e78.
dc.identifier.citedreferencePodsadecki TJ, Vrijens BC, Tousset EP, Rode RA, Hanna GJ. "White coat compliance" limits the reliability of therapeutic drug monitoring in HIV- 1- infected patients. HIV Clin Trials. 2008; 9: 238 - 246.
dc.identifier.citedreferenceGelman A, Carlin JB, Stern HS, Dunson DB, Vehtari A, Rubin DB. Bayesian Data Analysis. 3rd ed. Boca Raton, FL: Chapman & Hall/CRC Press; 2013.
dc.identifier.citedreferenceSpiegelhalter D, Thomas A, Best N, Lunn D. OpenBUGS user manual; 2014. http://www.openbugs.net/Manuals/Manual.html.
dc.identifier.citedreferenceJAGS: a program for analysis of Bayesian graphical models using Gibbs sampling; 2003.
dc.working.doiNOen
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
sim9321.pdf
Size:
1.231MB
Format:
PDF
View/Open
Name:
sim9321-sup-0001-supinfo.pdf
Size:
123.0KB
Format:
PDF
View/Open
Name:
sim9321_am.pdf
Size:
973.5KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.